RVL Pharma Issues Interim Q2 Sales From Its Droopy Eye Treatment

RVL Pharmaceuticals plc  (NASDAQ: RVLP ) announced preliminary Q2 FY22 sales from Upneeq of $8.4 million , up 42% sequentially. Upneeq (oxymetazoline hydrochloride ophthalmic solution) is an approved ophthalmic solution for blepharoptosis or droopy eyelids. The company also announced that from ... Full story available on Benzinga.com